EHC — Encompass Health Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $137.88
- YTD price return
- +29.90%
- YTD total return
- +30.86%
- Market cap
- 13.5B
- Enterprise value
- 17.4B
- Shares outstanding
- 98.1M
- 52W low
- $92.77
- 52W high
- $143.90
- From 52W high
- -4.18%
- From 52W low
- +48.63%
- 52W range
- 88%$92.77–$144
- Beta
- 0.77
Volume
- Rel volume
- 0.83×
- 30D volume
- 1.1M
- 30D $ vol
- 144.3M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$1.2M
- Insider net 1Y
- −$47.8M
Form 4 transactions by trade date, as filed; latest on file 2026-08-31.
Fundamentals
- Sales (ttm)
- 6.3B
- Sales/share
- $64.59
- EPS (ttm)
- $6.41
- FCF (ttm)
- 457.2M
- FCF/share
- $4.66
- Book value/share
- $27.32
- Net margin
- 10.17%
- ROE
- 24.03%
- ROA
- 8.52%
- Debt / equity
- 0.95×
- Current ratio
- 1.09
Growth (CAGR, ttm) · 10Y
- Sales
- +9.37%+10.54%+8.65%+5.85%
- Net income
- +19.13%+22.12%+9.65%+10.89%
- FCF
- +13.57%+21.50%+23.15%+0.52%
- Shares
- -2.48%-0.71%-0.28%+0.89%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +21.11%+22.33%+9.56%+10.37%
- Sales/share
- +12.15%+11.33%+8.95%+4.80%
- FCF/share
- +16.46%+22.40%+23.50%-0.37%
- Book value/share
- +15.83%+20.62%+8.09%+12.95%
- Dividend/share
- +11.44%+9.14%-6.98%-1.74%
- Price
- +23.12%+28.93%+22.21%+15.66%
- Total return
- +24.04%+29.85%+23.40%+17.25%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 21.5×
- Fwd P/E
- 20.5×
- P/S (ttm)
- 2.1×
- P/B (mrq)
- 5.0×
- P/FCF (ttm)
- 29.6×
- EV/EBITDA (fy)
- 12.9×
- EV/Sales (ttm)
- 2.7×
- FCF yield (ttm)
- 3.38%
- Dividend yield (fwd)Div yield
- 0.61%
- Dividend yield (ttm)
- 0.57%
- Dividend/share (fwd)
- $0.84
- Buyback yield (realized, 1y)
- 2.48%
- Shareholder yield (realized, 1y)
- 3.08%
- Buyback yield (cash, ttm)
- 2.07%
- Shareholder yield (cash, ttm)
- 2.64%
Vs own 10Y history
- P/E
- 70th
- P/S
- 96th
- P/B
- 93rd
- P/FCF
- 78th
Bar = where today’s multiple sits in EHC’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Net income
5Y CAGR +14.8%10Y CAGR +12.0%YoY +18.5%EPS (diluted)
5Y CAGR +14.2%10Y CAGR +11.2%YoY +21.0%Free cash flow
5Y CAGR +7.7%10Y CAGR +2.4%YoY +52.3%TTM: operating cash flow $1.3B, capex −$846.5M
Q3 2026: operating cash flow $362M, capex −$234.5M
Shares (diluted)
5Y +2.4%10Y +1.2%YoY −2.5%Dividend per share
5Y CAGR −8.5%10Y CAGR −2.0%YoY +10.5%About Encompass Health#
Data provided bySource: Twelve DataEncompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries. Its services combine medical, nursing, therapy, and ancillary support to help patients regain functional ability, independence, and quality of life. Encompass Health operates a national network of rehabilitation hospitals across the United States and Puerto Rico, making it a significant provider in the inpatient rehabilitation market. Based in Birmingham, Alabama, Encompass Health plays a central role in delivering coordinated recovery care for patients who need intensive, medically supervised rehabilitation after hospitalization.
Birmingham, AL·29,699 employees·Medical Care Facilities·encompasshealth.com·As of Oct 28, 2026
Recent filings#
- Nov 68-K · Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage
- Oct 28Earnings · Earnings release — EPS $1.52 vs $1.37 est. (+10.9%); revenue $1.61B (+9% y/y) 7.7%
- Aug 31Insider sale · Price Andrew L (Chief Accounting Officer) sold 5,211 shares for $630K at $120.93
- Aug 31Insider sale · Darby John Patrick (EVP, Gen Counsel & Secretary) sold 13,764 shares for $1.7M on 2 days since Aug 10
- Aug 10Insider sale · Tarr Mark J (President & CEO · Director) sold 173,148 shares for $21.7M at $125.46–$126.06
ETFs holding EHC#
19 of the 193 ETFs ChartRow carries live hold EHC. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VBR | Vanguard Small-Cap Value ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
